2021 ICD-10-CM Diagnosis Code C92.1

Chronic myeloid leukemia, BCR/ABL-positive

    2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
  • C92.1 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2021 edition of ICD-10-CM C92.1 became effective on October 1, 2020.
  • This is the American ICD-10-CM version of C92.1 - other international versions of ICD-10 C92.1 may differ.
Applicable To
  • Chronic myelogenous leukemia, Philadelphia chromosome (Ph1) positive
  • Chronic myelogenous leukemia, t(9;22) (
    ICD-10-CM Diagnosis Code Q34

    Other congenital malformations of respiratory system

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Type 2 Excludes
    • congenital central alveolar hypoventilation syndrome (G47.35)
    q34
    ;
    ICD-10-CM Diagnosis Code Q11

    Anophthalmos, microphthalmos and macrophthalmos

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    q11
    )
  • Chronic myelogenous leukemia with crisis of blast cells
Type 1 Excludes
Type 1 Excludes Help
A type 1 excludes note is a pure excludes. It means "not coded here". A type 1 excludes note indicates that the code excluded should never be used at the same time as C92.1. A type 1 excludes note is for used for when two conditions cannot occur together, such as a congenital form versus an acquired form of the same condition.
  • atypical chronic myeloid leukemia BCR/ABL-negative (
    ICD-10-CM Diagnosis Code C92.2

    Atypical chronic myeloid leukemia, BCR/ABL-negative

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    C92.2-
    )
  • chronic myelomonocytic leukemia (
    ICD-10-CM Diagnosis Code C93.1

    Chronic myelomonocytic leukemia

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Applicable To
    • Chronic monocytic leukemia
    • CMML-1
    • CMML-2
    • CMML with eosinophilia
    Code Also
    • , if applicable, eosinophilia (D72.18)
    C93.1-
    )
  • chronic myeloproliferative disease (
    ICD-10-CM Diagnosis Code D47.1

    Chronic myeloproliferative disease

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Chronic neutrophilic leukemia
    • Myeloproliferative disease, unspecified
    Type 1 Excludes
    • atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
    • chronic myeloid leukemia BCR/ABL-positive (C92.1-)
    • myelofibrosis NOS (D75.81)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • secondary myelofibrosis NOS (D75.81)
    D47.1
    )
The following code(s) above C92.1 contain annotation back-references
Annotation Back-References
In this context, annotation back-references refer to codes that contain:
  • Applicable To annotations, or
  • Code Also annotations, or
  • Code First annotations, or
  • Excludes1 annotations, or
  • Excludes2 annotations, or
  • Includes annotations, or
  • Note annotations, or
  • Use Additional annotations
that may be applicable to C92.1:
  • C00-D49
    2021 ICD-10-CM Range C00-D49

    Neoplasms

    Note
    • Functional activity
    • All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
    • Morphology [Histology]
    • Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
    • Primary malignant neoplasms overlapping site boundaries
    • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
    • Malignant neoplasm of ectopic tissue
    • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
    Neoplasms
  • C81-C96
    2021 ICD-10-CM Range C81-C96

    Malignant neoplasms of lymphoid, hematopoietic and related tissue

    Type 2 Excludes
    • Kaposi's sarcoma of lymph nodes (C46.3)
    • secondary and unspecified neoplasm of lymph nodes (C77.-)
    • secondary neoplasm of bone marrow (C79.52)
    • secondary neoplasm of spleen (C78.89)
    Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C92
    ICD-10-CM Diagnosis Code C92

    Myeloid leukemia

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code
    Includes
    • granulocytic leukemia
    • myelogenous leukemia
    Type 1 Excludes
    • personal history of leukemia (Z85.6)
    Myeloid leukemia
Clinical Information
  • A chronic myeloproliferative neoplasm characterized by the expression of the bcr-abl1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and imatinib therapy delay disease progression and prolong overall survival.
  • A slowly progressing disease in which too many white blood cells are made in the bone marrow.
  • Chronic leukemia in which myeloid progenitor cells predominate; the hallmark of cml, the philadelphia chromosome, is a reciprocal translocation between chromosomes 9 and 22 which activates the proto- oncogene c-abl.
  • Clonal hematopoetic disorder caused by an acquired genetic defect in pluripotent stem cells. It starts in myeloid cells of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (leukemia, myeloid, chronic phase) lasting up to 7 years, to an advanced phase composed of an accelerated phase (leukemia, myeloid, accelerated phase) and blast crisis.
  • leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (cml), there are too many granulocytes, a type of white blood cell.most people with cml have a gene mutation (change) called the philadelphia chromosome.sometimes cml does not cause any symptoms. If you have symptoms, they may include:
    • fatigue
    • weight loss
    • night sweats
    • fever
    • pain or a feeling of fullness below the ribs on the left side
    tests that examine the blood and bone marrow diagnose cml. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute
Code History
  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
Code annotations containing back-references to C92.1:
  • Type 1 Excludes: D47.1
    ICD-10-CM Diagnosis Code D47.1

    Chronic myeloproliferative disease

      2016 2017 2018 2019 2020 2021 Billable/Specific Code
    Applicable To
    • Chronic neutrophilic leukemia
    • Myeloproliferative disease, unspecified
    Type 1 Excludes
    • atypical chronic myeloid leukemia BCR/ABL-negative (C92.2-)
    • chronic myeloid leukemia BCR/ABL-positive (C92.1-)
    • myelofibrosis NOS (D75.81)
    • myelophthisic anemia (D61.82)
    • myelophthisis (D61.82)
    • secondary myelofibrosis NOS (D75.81)

Diagnosis Index entries containing back-references to C92.1:
  • Leukemia, leukemic C95.9-
    ICD-10-CM Diagnosis Code C95.9-

    Leukemia, unspecified

      2016 2017 2018 2019 2020 2021 Non-Billable/Non-Specific Code

ICD-10-CM Codes Adjacent To C92.1
C91.Z2 …… in relapse
C91.9 Lymphoid leukemia, unspecified
C91.90 …… not having achieved remission
C91.91 …… in remission
C91.92 …… in relapse
C92 Myeloid leukemia
C92.0 Acute myeloblastic leukemia
C92.00 …… not having achieved remission
C92.01 …… in remission
C92.02 …… in relapse
C92.1 Chronic myeloid leukemia, BCR/ABL-positive
C92.10 …… not having achieved remission
C92.11 …… in remission
C92.12 …… in relapse
C92.2 Atypical chronic myeloid leukemia, BCR/ABL-negative
C92.20 …… not having achieved remission
C92.21 …… in remission
C92.22 …… in relapse
C92.3 Myeloid sarcoma
C92.30 …… not having achieved remission
C92.31 …… in remission

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.